menu
    • menu
    [{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2022","type":"Not Applicable","leadProduct":"AMTX-100","moa":"NF-kB","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Amytrx Therapeutics","pharmaFlowCategory":"DU","therapeuticArea":"Dermatology","country":"","productType":"Peptide","year":"2023","type":"Not Applicable","leadProduct":"AMTX-100 CF3","moa":"","graph1":"Dermatology","graph2":"Phase I\/ Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Cream","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"7","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"},{"orgOrder":0,"company":"Amarex Clinical Research","sponsor":"Aim ImmunoTech","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Rintatolimod","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Amarex Clinical Research","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Amarex Clinical Research \/ Amarex Clinical Research","highestDevelopmentStatusID":"8","companyTruncated":"Amarex Clinical Research \/ Amarex Clinical Research"}]

    Find Clinical Drug Pipeline Developments & Deals by Amarex Clinical Research

    Menu

    Amarex Clinical Research

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Amarex Clinical Research

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            AIM ImmunoTech Enrolls and Doses First Subject in Phase 2 Study Evaluating Ampligen for the Treatment of Post-...

                            Details : Ampligen® (rintatolimod) is an immuno-modulator with broad spectrum activity and evaluating Phase 2 Study for the Treatment of people with post-COVID conditions.

                            Brand Name : Ampligen

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            July 10, 2023

                            Lead Product(s) : Rintatolimod

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : Aim ImmunoTech

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Amarex Clinical Research

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMTX-100 CF3

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Recipient : Amytrx Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amytrx Therapeutics Announces Open Enrollment for Phase 2b Clinical Trial of AMTX-100 CF3, a Promising Anti-In...

                            Details : AMTX-100 CF3, is a topical formulation anti-inflammatory peptide therapeutic designed to treat patients suffering from mild to moderate atopic dermatitis.

                            Brand Name : AMTX-100 CF3

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 28, 2023

                            Lead Product(s) : AMTX-100 CF3

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Amytrx Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Amarex Clinical Research

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed

                            Amarex Clinical Research

                            U.S.A arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Study Phase : Phase I/ Phase II

                            Recipient : Amytrx Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Amytrx Therapeutic's AMTX-100 CF3 Moves to Phase II Clinical Trial for Atopic Dermatitis

                            Details : AMTX-100 CF3, its leading drug candidate, is known for its ability to transport across membranes, address inflammation and modulate immune mediated diseases instead of simply inhibiting inflammation.

                            Brand Name : AMTX-100

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            June 09, 2022

                            Lead Product(s) : AMTX-100

                            Therapeutic Area : Dermatology

                            Highest Development Status : Phase I/ Phase II

                            Recipient : Amytrx Therapeutics

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth